Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1997-10-02
1999-07-13
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
436519, 435 72, 435 721, 530300, 536 231, G01N 3353, G01N 33554, C07K 400
Patent
active
059225483
ABSTRACT:
Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carries with it the information of its identity or method of synthesis. After washing away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstrates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade.
REFERENCES:
Guerif, F., et al., "Screening of Pig cDNA Expression Library with Human Serum in Order to Identify New Xenoantigens," Cambridge Sci. Abs., Acc. Nr.: 01971387 3820007, 1995., Transplantation proceedings, 27(4):2941 (1995).
Galili, U., et al., "Evolutionary Relationship Between the Natural Anti-Gal Antibody and the Gal.alpha.1.fwdarw. 3Gal Epitope in Primates," PNAS, USA, 84:1369-1373 (1987).
Galili, U., et al., "One Percent of Human Circulating B Lymphocytes are Capable of Producing the Natural Anti-Gal Antibody," Blood, 82(8):2485-2493 (1993).
Galili, U., et al., "Human Natural Anti-.alpha.-Galactosyl IgG. II. The Specific Recognition of .alpha.(1.fwdarw. 3)-Linked Galactose Residues," J. Exp. Med., 162:573-582 (1985).
Nakagawa et al (FEBS Letters, 408:301-305, 1997.
Ennas et al (Cancer Research, 57:2035-2041), 1997.
Buelow Roland
Lussow Alexander R.
Pouletty Philippe
Hutzell Paula K.
SangStat Medical Corporation
Trecartin Richard F.
Ungar Susan
LandOfFree
Anti .alpha.-gal screening technique does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti .alpha.-gal screening technique, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti .alpha.-gal screening technique will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2274989